Tina Lee
Research Subjects
Tina Lee has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Chenxiao Hu
The First Hospital of Lanzhou University, China
4 shared publications- Dylan Lee
Curastrategix Health, USA
4 shared publications Luna Lee
Northeast Ohio Neighborhood Health Services, Inc., USA
4 shared publicationsLaure C. Bouchez
Adel's SAS, France
2 shared publicationsNicolas Melin
Adel's SAS, France
2 shared publications- Xiangquan Ren
East China University of Political Science and Law, Shanghai, China
1 shared publication
Latest Publications
- 2 May 2026
- Published by IGI Global Scientific Publishing
- p. 1-24
Introduction: The Political Economy of Global Healthcare Industries
This introduction chapter outlines the conceptual foundations and purpose of the volume The Political Economy of Global Healthcare Industries: States, Markets, and Power. It situates the globalization of healthcare within broader transformations of twenty-first-century capitalism and explains how this volume analyzes healthcare as both an economic system and a moral order. Drawing on political economy, the chapter examines how states, markets, and power interact to shape innovation, regulation, and inequality across global health industries. It highlights key themes of the book—financialization, industrial policy, digitalization, and health security—while establishing the analytical framework linking macroeconomic structures to ethical and institutional dimensions of governance. This chapter provides readers with the theoretical context, scope, and objectives that guide the contributions that follow.
- 2 May 2026
- Published by IGI Global Scientific Publishing
- p. 1-24
Introduction: The Political Economy of Global Healthcare Industries
This introduction chapter outlines the conceptual foundations and purpose of the volume The Political Economy of Global Healthcare Industries: States, Markets, and Power. It situates the globalization of healthcare within broader transformations of twenty-first-century capitalism and explains how this volume analyzes healthcare as both an economic system and a moral order. Drawing on political economy, the chapter examines how states, markets, and power interact to shape innovation, regulation, and inequality across global health industries. It highlights key themes of the book—financialization, industrial policy, digitalization, and health security—while establishing the analytical framework linking macroeconomic structures to ethical and institutional dimensions of governance. This chapter provides readers with the theoretical context, scope, and objectives that guide the contributions that follow.
- 2 May 2026
- Published by IGI Global Scientific Publishing
- p. 55-86
Pandemic Lessons
This chapter examines the COVID-19 pandemic as a systemic stress test of global health governance, revealing the tensions between state sovereignty, market logic, and multilateral solidarity. It situates pandemic responses within the broader political economy of healthcare, analyzing how intellectual property regimes, supply-chain concentration, and fiscal asymmetries shaped inequities in access to vaccines, diagnostics, and therapeutics. Comparative case studies from the United States, China, and low- and middle-income countries illustrate divergent outcomes arising from variations in state capacity, industrial policy, and social protection. The chapter argues that pandemic resilience requires reimagining health as a global public good, diversifying regional production, reforming intellectual-property frameworks, and embedding equity into international law. Through an integrated analysis of governance, finance, and justice, it proposes a new paradigm of cooperative preparedness grounded in transparency, inclusivity, and sustainable solidarity.
- 2 May 2026
- Published by IGI Global Scientific Publishing
- p. 55-86
Pandemic Lessons
This chapter examines the COVID-19 pandemic as a systemic stress test of global health governance, revealing the tensions between state sovereignty, market logic, and multilateral solidarity. It situates pandemic responses within the broader political economy of healthcare, analyzing how intellectual property regimes, supply-chain concentration, and fiscal asymmetries shaped inequities in access to vaccines, diagnostics, and therapeutics. Comparative case studies from the United States, China, and low- and middle-income countries illustrate divergent outcomes arising from variations in state capacity, industrial policy, and social protection. The chapter argues that pandemic resilience requires reimagining health as a global public good, diversifying regional production, reforming intellectual-property frameworks, and embedding equity into international law. Through an integrated analysis of governance, finance, and justice, it proposes a new paradigm of cooperative preparedness grounded in transparency, inclusivity, and sustainable solidarity.
- 2 May 2026
- Published by IGI Global Scientific Publishing
- p. 25-54
How Drug Pricing Reflects National Values Comparing the U.S. and Europe
This article analyzes how national values shape pharmaceutical pricing, comparing the United States and Europe as distinct political economies of health. Drug prices reflect not only market forces but the moral and institutional choices by which societies balance innovation, equity, and fiscal legitimacy. The U.S. model, delegated capitalism, links public research to private profit, generating rapid innovation but deep inequality. The European model, embedded corporatism, ties reimbursement to therapeutic value, achieving solidarity yet slower adoption. Tracing postwar development through the 2008 financial crisis and COVID-19, the study shows how both systems adapt under stress and how transatlantic interaction now defines global norms of affordability, state authority, and technological sovereignty.
- 2 May 2026
- Published by IGI Global Scientific Publishing
- p. 25-54
How Drug Pricing Reflects National Values Comparing the U.S. and Europe
This article analyzes how national values shape pharmaceutical pricing, comparing the United States and Europe as distinct political economies of health. Drug prices reflect not only market forces but the moral and institutional choices by which societies balance innovation, equity, and fiscal legitimacy. The U.S. model, delegated capitalism, links public research to private profit, generating rapid innovation but deep inequality. The European model, embedded corporatism, ties reimbursement to therapeutic value, achieving solidarity yet slower adoption. Tracing postwar development through the 2008 financial crisis and COVID-19, the study shows how both systems adapt under stress and how transatlantic interaction now defines global norms of affordability, state authority, and technological sovereignty.
- 2 January 2026
- Published by IGI Global Scientific Publishing
- p. 119-160
Migrant Leadership in Cross-Border Biotech and Health Innovation
This chapter, per the authors, reframes migrant founders as institutional architects who assemble cross-border biomedical pipelines to correct misalignments between national innovation systems and transnational health needs. It introduces Transnational Corrective Innovation and tests six propositions linking dual-regime regulatory fluency, diaspora-anchored finance, early multi-ancestry evidence, capability-based geographic unbundling, privacy-preserving data design, and regulatory reliance to measurable gains in time-to-trial, capital inflection, evidence quality, AI validation, and multi-market access. Using a comparative, de-identified multi-case design (2017–2025) across therapeutics, digital epidemiology, and diagnostics, the chapter operationalizes lean indicators from public, auditable sources. Findings show earlier first-in-human starts, faster institutional financing, fewer representativeness queries, accelerated validation under GDPR and the AI Act, and shorter secondary approval lags, with policy and governance templates distilled for regulators, funders, and universities.
- 2 January 2026
- Published by IGI Global Scientific Publishing
- p. 119-160
Migrant Leadership in Cross-Border Biotech and Health Innovation
This chapter, per the authors, reframes migrant founders as institutional architects who assemble cross-border biomedical pipelines to correct misalignments between national innovation systems and transnational health needs. It introduces Transnational Corrective Innovation and tests six propositions linking dual-regime regulatory fluency, diaspora-anchored finance, early multi-ancestry evidence, capability-based geographic unbundling, privacy-preserving data design, and regulatory reliance to measurable gains in time-to-trial, capital inflection, evidence quality, AI validation, and multi-market access. Using a comparative, de-identified multi-case design (2017–2025) across therapeutics, digital epidemiology, and diagnostics, the chapter operationalizes lean indicators from public, auditable sources. Findings show earlier first-in-human starts, faster institutional financing, fewer representativeness queries, accelerated validation under GDPR and the AI Act, and shorter secondary approval lags, with policy and governance templates distilled for regulators, funders, and universities.
- 12 December 2025
- Published by IGI Global Scientific Publishing
- p. 193-222
Isolation in White Coats
This chapter reframes loneliness among globally mobile healthcare professionals as a structural outcome of political economy rather than an individual shortcoming. Using an interdisciplinary review and a U.S–China comparison (with selective UK references), it traces how migration regimes, credentialing bottlenecks, institutional hierarchies, and market logics jointly produce isolation among migrant clinicians. Four interlocking dynamics emerge—bureaucratic precarity, emotional dislocation, professional invisibility, and commodification of care—each linked to burnout, attrition, and underused cultural–linguistic assets. We translate this synthesis into multi-level remedies: institution-level onboarding, mentorship, mental-health supports, and anti-bias systems; national reforms to visas, fair-contract enforcement, and credential recognition; and cross-border adherence to the WHO Code, bilateral supports, and better migration data.
- 12 December 2025
- Published by IGI Global Scientific Publishing
- p. 193-222
Isolation in White Coats
This chapter reframes loneliness among globally mobile healthcare professionals as a structural outcome of political economy rather than an individual shortcoming. Using an interdisciplinary review and a U.S–China comparison (with selective UK references), it traces how migration regimes, credentialing bottlenecks, institutional hierarchies, and market logics jointly produce isolation among migrant clinicians. Four interlocking dynamics emerge—bureaucratic precarity, emotional dislocation, professional invisibility, and commodification of care—each linked to burnout, attrition, and underused cultural–linguistic assets. We translate this synthesis into multi-level remedies: institution-level onboarding, mentorship, mental-health supports, and anti-bias systems; national reforms to visas, fair-contract enforcement, and credential recognition; and cross-border adherence to the WHO Code, bilateral supports, and better migration data.